Team Members

Ben Zeskind, PhD, MBA

Co-Founder and CEO

Ben Zeskind, PhD, MBA

Co-Founder and CEO

Dr. Zeskind co-founded Immuneering in 2008 with the goal of leveraging high-throughput data to improve pharma R&D. He is an inventor on numerous patents assigned to both Immuneering's partners and the company itself, and has published extensively in peer-reviewed journals. He trained at the Massachusetts Institute of Technology, earning a Ph.D. in Bioengineering in 2006 and an S.B. in Electrical Engineering and Computer Science in 2003. He also earned an MBA at Harvard Business School in 2008, where he was recognized as a Baker Scholar, the highest award for distinction.

Brett Hall, PhD

Chief Scientific Officer

Brett Hall, PhD

Chief Scientific Officer

Dr. Hall is a pharmaceutical (Janssen/J&J; Medimmune/AZ) and biotechnology veteran (Molecular Response; Asellus Therapeutics) with drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. He was the translational lead for Sylvant® (siltuximab) and Imbruvica® (ibrutinib) throughout clinical development, and his translational medicine teams developed and executed translational strategies for both Darzalex® (daratumumab) and Imfinzi® (durvalumab). Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences and holds multiple patents for drug pharmacology and discovery. Prior to joining pharma in 2008, he served in the United States Air Force; then worked as a Series 6 and 63 licensed investment banker. After completing his graduate and postdoctoral studies, Dr. Hall was a tenure-track assistant professor at Ohio State University. His laboratory focused on development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers.

Kevin D. Fowler, PhD

Vice President, Translational Research

Kevin D. Fowler, PhD

Vice President, Translational Research

Dr. Fowler brings deep expertise in biology and computational biology to our team. He joined Immuneering after completing his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology. His doctoral research was focused on computational immunology and signal integration in immune cell biology, and he conducted research at Harvard Medical School.

Sarah Kolitz, PhD

Vice President, Translational Medicine

Sarah Kolitz, PhD

Vice President, Translational Medicine

Dr. Kolitz brings expertise in teasing apart biological mechanisms to our team. She conducted her postdoctoral research in Biological Engineering at the Massachusetts Institute of Technology, after earning a Ph.D. in Biophysics and Biophysical Chemistry from the Johns Hopkins University School of Medicine.

Rebecca Kusko, PhD

SVP, Head of R&D

Rebecca Kusko, PhD

SVP, Head of R&D

Dr. Kusko is a computational biologist with expertise in translating NGS and other genomic data to clinical discoveries. She has integrated directly with clinicians on study design, as well as with lab scientists in functional genomics, to plan molecular biology and validation experiments. After completing her undergraduate degree in Biological Engineering at Massachusetts Institute of Technology, she went on to complete her Ph.D. in Computational Biomedicine at the Boston University School of Medicine. Her doctoral thesis focused on the transcriptome in Chronic Obstructive Pulmonary Disease, or COPD, and lung cancer in non-smokers.

Andrew Lysaght, PhD

SVP, Head of Bioinformatics Services

Andrew Lysaght, PhD

SVP, Head of Bioinformatics Services

Dr. Lysaght integrates years of experience with biological expression data together with a rigorous background in engineering fundamentals to provide expertise in customized data analysis with an eye for practical and actionable results. He earned a Ph.D. from the joint Harvard-MIT Program in Health Sciences and Technology, where he worked alongside leading clinicians of the Massachusetts Eye and Ear Infirmary to identify changes in inner ear transcription and translation during delayed onset hearing loss.

Yoonjeong Cha

Director, Genomics

Yoonjeong Cha

Director, Genomics

Since joining Immuneering, Ms. Cha has developed an expertise in multi-omic integration and mutation prioritization in cancer data. She holds a B.S. in Computer Science and Molecular Biology from the Massachusetts Institute of Technology. Before graduating, she spent a year at the Bioinformatics Institute at Seoul National University working on a method to identify differentially expressed signaling pathways. She also spent a summer at the Robert Koch Institute in Berlin, Germany, analyzing genomic and proteomic data from viruses. She won first place in the 10th Annual Merck/BE-BMES Undergraduate Research Poster Session.

Gregory Koytiger, PhD

SVP, Head of Artificial Intelligence

Gregory Koytiger, PhD

SVP, Head of Artificial Intelligence

Dr. Koytiger leads Immuneering’s work in the development of novel algorithms to accelerate drug discovery. We call our platform Fluency for its ability to read, understand and generate biological sequence data by leveraging the latest advancements in neural networks. Dr. Koytiger brings deep expertise at the interface of chemistry, biology and artificial intelligence. He completed his Ph.D. at Harvard's Department of Chemistry and Chemical Biology where he analyzed the network properties of oncogenes using quantitative protein microarrays. In his post-doctoral work at the Department of Systems Biology in Harvard Medical School, he co-developed a predictive model to assess the quantitative impact of cancer mutations on protein-protein interaction networks from protein sequences.

Jenny Zhang, PhD

Director, Genomic Data Science

Jenny Zhang, PhD

Director, Genomic Data Science

Dr. Zhang extracts actionable insights from genomic data by combining cutting-edge data science techniques with expertise in experiment design and cancer biology. During her data science fellowship at The Data Incubator, she utilized distributed computing, network analysis, and machine learning to reveal patterns within large textual and numerical datasets. She graduated from the Massachusetts Institute of Technology with a B.S. in Physics, and Duke University with a Ph.D. in Genetics and Genomics. In her doctoral work, she developed novel experimental and bioinformatic methods to generate and analyze terabytes of next-generation sequencing data towards understanding the mutational underpinnings of lymphoma.

Jermaine Ross, PhD

Director, Translational Medicine

Jermaine Ross, PhD

Director, Translational Medicine

For over a decade, Dr. Ross studied at the National Institutes of Health, where he designed and conducted original research in the field of bioinformatics and comparative genomics. His work has been recognized for enhancing computational methods to identify and analyze molecular mechanisms that regulate neurogenesis. Dr. Ross has developed and employed machine learning and bioinformatic algorithms to decode the combinatorial logic of noncoding DNA that control gene expression programs. He earned his PhD degree in Neuroscience from Brown University.

Renan Escalante-Chong, PhD

Director, Systems Biology

Renan Escalante-Chong, PhD

Director, Systems Biology

Dr. Escalante-Chong is passionate about integrating the massive amounts of data generated in modern biology to transform disease management and treatment. He did his Ph.D. at the Department of Systems Biology at Harvard Medical School where he used quantitative molecular genetics to dissect signaling pathways. He completed his postdoctoral training at the Department of Biological Engineering at the Massachusetts Institute of Technology where he worked with the interdisciplinary teams of neuroLINCS and answerALS to generate molecular signatures of the neurodegenerative diseases ALS and SMA.

Jason Funt, PhD

Vice President, Computational Biology

Jason Funt, PhD

Vice President, Computational Biology

Dr. Funt’s focus is in synthesizing actionable insight from complex, heterogeneous high-dimensional data. He earned his Ph.D. in Computational and Systems Biology from MIT’s Biology Department. His thesis research, at both the Massachusetts Institute of Technology and the Broad Institute, focused on mapping evolutionary pathways of drug resistance from genomic and transcriptomic profiling of the pathogen Candida albicans.

Matthew Ung, PhD

Director, Systems Pharmacology

Matthew Ung, PhD

Director, Systems Pharmacology

Dr. Ung is a computational biologist with extensive experience in applying data science techniques to extract translational insight from biological and disease data. Dr. Ung received his Ph.D. from the Geisel School of Medicine at Dartmouth in the Department of Molecular and Systems Biology. During this time, he primarily focused on developing computational approaches to integrate diverse genomic and clinical datasets to pinpoint the genetic aberrations underlying several cancer types and to identify potential therapeutic candidates. In addition, Dr. Ung’s interdisciplinary background has allowed him to author and co-author several studies across diverse topics including experimental pharmacology, epidemiology, epigenetics, and biological networks.

John Brothers II, PhD

Director, Bioinformatics

John Brothers II, PhD

Director, Bioinformatics

Dr. Brothers is a Bioinformatician with expertise in NGS data analysis and specializes in transcriptomics. He brings industry experience with working in team-based collaborative environments with clinicians, experimentalists, and bioinformaticists. He graduated with a B.S. in Bioinformatics from the Rochester Institute of Technology and a Ph.D. in Bioinformatics from Boston University. His doctoral thesis focused on identifying splice variants and novel genes associated with chronic lung disease in order to better characterize the lung transcriptome from patients with Chronic Obstructive Pulmonary Disease or Idiopathic Pulmonary Fibrosis.

Vincent Xue, PhD

Associate Director, Systems Pharmacology

Vincent Xue, PhD

Associate Director, Systems Pharmacology

Dr. Xue is a computational biologist passionate about extracting insight from biological datasets. He completed his Ph.D. at the Massachusetts Institute of Technology in the Department of Computational and Systems Biology. His thesis research applied a data-driven approach to the design of tight and specific peptides to Bcl-2 family proteins, which are most notable for their role in regulating apoptosis.

Melissa Martin

Executive Administrative Assistant

Melissa Martin

Executive Administrative Assistant

Ms. Martin has several years of experience in office administration in various industries, as well as a broad background in customer relations, social media and marketing, human resources and recruiting, and finance. She holds a B.S. in Communications from Fitchburg State University.